Search results for "Partial"

showing 10 items of 1477 documents

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Nov…

2017

Abstract Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. Here, we evaluate the activity of darolutamide in enzalutamide-resistant castration resistant prostate cancer (CRPC) as well as in AR mutants detected in patients after treatment with enzalutamide, abiraterone, or bicalutamide. Darolutamide significantly inhibited cell growth and AR transcriptional activity in enzalutamide-resistant MR49F cells in vitro, and led to decreased tumor volume and serum prostate-specific antigen l…

0301 basic medicineMaleModels MolecularTime FactorsTranscription GeneticProtein ConformationProstate cancerchemistry.chemical_compoundMice0302 clinical medicineMolecular Targeted TherapyTumor BurdenDarolutamideReceptors Androgen030220 oncology & carcinogenesisBenzamidesmedicine.drugSignal Transductionmedicine.medical_specialtyBicalutamideUrologyPartial agonist03 medical and health sciencesStructure-Activity RelationshipIn vivoInternal medicineCell Line TumorNitrilesPhenylthiohydantoinmedicineAndrogen Receptor AntagonistsEnzalutamideAnimalsHumansCell ProliferationDose-Response Relationship DrugCell growthbusiness.industryProstatic Neoplasmsmedicine.diseaseXenograft Model Antitumor AssaysAndrogen receptor030104 developmental biologyEndocrinologychemistryDrug Resistance NeoplasmMutationCancer researchPyrazolesbusinessEuropean urology
researchProduct

2020

Background Small sample sizes combined with multiple correlated endpoints pose a major challenge in the statistical analysis of preclinical neurotrauma studies. The standard approach of applying univariate tests on individual response variables has the advantage of simplicity of interpretation, but it fails to account for the covariance/correlation in the data. In contrast, multivariate statistical techniques might more adequately capture the multi-dimensional pathophysiological pattern of neurotrauma and therefore provide increased sensitivity to detect treatment effects. Results We systematically evaluated the performance of univariate ANOVA, Welch’s ANOVA and linear mixed effects models …

0301 basic medicineMultivariate statisticsMultidisciplinaryUnivariateContrast (statistics)Linear discriminant analysis03 medical and health sciences030104 developmental biology0302 clinical medicineMultivariate analysis of variancePrincipal component analysisPartial least squares regressionStatisticsAnalysis of variance030217 neurology & neurosurgeryMathematicsPLOS ONE
researchProduct

Compassionate use of everolimus for refractory epilepsy in a patient with MTOR mosaic mutation

2020

Abstract The MTOR gene encodes the mechanistic target of rapamycin (mTOR), which is a core component of the PI3K-AKT-mTOR signaling pathway. Postzygotic MTOR variants result in various mosaic phenotypes, referred to in OMIM as Smith-Kinsgmore syndrome or focal cortical dysplasia. We report here the case of a patient, with an MTOR mosaic gain-of-function variant (p.Glu2419Lys) in the DNA of 41% skin cells, who received compassionate off-label treatment with everolimus for refractory epilepsy. This 12-year-old-girl presented with psychomotor regression, intractable seizures, hypopigmentation along Blaschko's lines (hypomelanosis of Ito), asymmetric regional body overgrowth, and ocular anomali…

0301 basic medicineOncologyCompassionate Use Trialsmedicine.medical_specialty[SDV]Life Sciences [q-bio]030105 genetics & heredityMuscle hypertrophyCraniofacial Abnormalities03 medical and health sciencesInternal medicineGeneticsmedicineHumansEverolimusChildMechanistic target of rapamycinProtein Kinase InhibitorsGenetics (clinical)PI3K/AKT/mTOR pathwayHypopigmentationEverolimusbiologybusiness.industryMosaicismTOR Serine-Threonine KinasesNeuropsychologyGeneral MedicineCortical dysplasiamedicine.disease3. Good healthClinical trialMalformations of Cortical Development[SDV] Life Sciences [q-bio]030104 developmental biologyPhenotypeGain of Function Mutationbiology.proteinFemaleEpilepsies Partialmedicine.symptombusinessmedicine.drug
researchProduct

Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT)

2017

Abstract Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) is a rare benign lesion characterized by slow growth, infiltrative behavior and high rate of local recurrences. Only one case has been described in retroperitoneum, at renal hilum, but not involving pelvis or parenchyma. Here we present the first case of PHAT arising in the renal parenchyma. A nodular lesion in right kidney lower pole was diagnosed to a 61 year old woman. The patient underwent right nephrectomy. Microscopically, the lesion showed solid and pseudo-cystic components with hemorrhagic areas characterized by aggregates of ectatic blood vessels. Pleomorphic cells were characterized by large eosinophilic cytoplasm with irre…

0301 basic medicinePathologymedicine.medical_specialtymedicine.medical_treatment2734Pleomorphic Hyalinizing Angiectatic Tumor (PHAT)Renal tumorKidneyRenal hilumNephrectomyPathology and Forensic MedicineLesion03 medical and health sciences0302 clinical medicineEctasiaParenchymaEosinophilicmedicineHumansPartial nephrectomyKidneybusiness.industryKidney NeoplasmCell BiologyMiddle AgedKidney NeoplasmsNephrectomyTreatment Outcome030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisImmunohistochemistryFemalemedicine.symptombusinessHumanPathology - Research and Practice
researchProduct

Statement of the Prolamin Working Group on the Determination of Gluten in Fermented Foods Containing Partially Hydrolyzed Gluten

2021

On August 12, 2020, the U.S. Food and Drug Administration (FDA) has finalized a rule related to gluten-free labeling for foods containing fermented, hydrolyzed ingredients. The FDA believes that there is no scientifically valid analytical method effective for determining gluten in fermented or hydrolyzed foods. In the absence of an analytical method, the FDA has decided to evaluate gluten-free claims on these foods based only on evidence that the food or ingredient used is gluten-free before fermentation or hydrolysis. For example, barley-based beers from which gluten is removed during brewing using special filtration, adsorption and/or enzymatic treatment are therefore excluded from bearin…

0301 basic medicineanalysifermented foodanalysisEndocrinology Diabetes and MetabolismIngredientProlaminFood scienceIngredient0302 clinical medicinehydrolysed beer[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceFermentation in food processingComputingMilieux_MISCELLANEOUS2. Zero hungerchemistry.chemical_classificationNutrition and DieteticsbiologyChemistryHydrolysisdigestive oral and skin physiologyfood and beveragesQuímicaChemistryFermentation in food processingProlamin Working Groupgluten-free foodpartially hydrolyzed glutenlcsh:Nutrition. Foods and food supplyLife sciences; biologyOpinioncompetitive ELISAlcsh:TX341-641030209 endocrinology & metabolismdigestive systemFood and drug administration03 medical and health sciencesHydrolysisddc:570ProlaminLC-MS/MSFood and drug administrationNutrition030109 nutrition & dieteticsbusiness.industrynutritional and metabolic diseasesBrewingGlutendigestive system diseasesPlant BreedingglutenFermentationbiology.proteinBrewingFermentation[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionceliac diseaseFrontiers in Nutrition
researchProduct

Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema

2016

<b><i>Objective:</i></b> To evaluate whether activated partial thromboplastin time (APTT) could be used in the laboratory diagnosis of hereditary or acquired angioedema (HAE or AAE) with and without C1 inhibitor (C1-INH) deficiency. <b><i>Methods:</i></b> In a prospective investigation, APTT and other coagulation parameters were determined in 149 adult patients with various types of angioedema and in 26 healthy participants (HP). <b><i>Results:</i></b> Mean APTT was significantly shortened in HAE-C1-INH type I (p < 0.0001) and type II (p = 0.0017) and in AAE-C1-INH (p < 0.0001) compared to the HP. APTT was shorten…

0301 basic medicinemedicine.medical_specialtyImmunologyAcquired angioedemaGastroenterologyC1-inhibitorDiagnosis Differential03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansImmunology and Allergyheterocyclic compoundsProspective StudiesAngioedemaProspective cohort studyBlood CoagulationBlood coagulation testAngioedemamedicine.diagnostic_testbiologybusiness.industryAngioedemas HereditaryComplement C4General Medicinerespiratory systembacterial infections and mycosesrespiratory tract diseases030104 developmental biologyCoagulationPredictive value of testsAnesthesiaImmunologybiology.proteinPartial Thromboplastin TimeBlood Coagulation Testsmedicine.symptombusinessComplement C1 Inhibitor ProteinBiomarkerscirculatory and respiratory physiologyPartial thromboplastin timeInternational Archives of Allergy and Immunology
researchProduct

Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma

2019

Abstract Background ABBV-181 is a humanized anti-PD1 monoclonal antibody; dose finding and early safety, PK and pharmacodynamic data have been reported (ESMO18). This report summarizes data from the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts in the Ph1 FIH study (NCT03000257). Methods Patients (pts) with previously treated, advanced HNSCC and NSCLC received ABBV-181 IV, 250 mg Q2W or 500 mg Q4W to progression. Response was assessed by RECIST v1.1 and iRECIST. Results As of April 2019, 81 pts were dosed. Table . 1288P n (%) HNSCC n = 41 NSCLC n = 40 Median days on treatment, range 72, 1–407 71, 1–421 Dose: 250 mg/500 mg 31/10 19/21 …

0301 basic medicinemedicine.medical_specialtybusiness.industryAnti pd 1Physical healthStock optionsHematology03 medical and health sciencesNeoplasm progressionDose finding030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinePartial responseMedicinemedicine.symptombusinessHead and neck carcinomaConfusionAnnals of Oncology
researchProduct

Multidisciplinary oral rehabilitation in partially edentulous adult patients with malocclusion: a cross-sectional survey study

2018

Background A cross-sectional survey was conducted to gather information regarding the opinion of Brazilian specialists in both orthodontics and implantology on multidisciplinary oral rehabilitation in partially edentulous patients with malocclusion. Material and methods A total of 305 specialists participated in a telephone survey and answered an ad hoc 10-item questionnaire, including the request of total skull cone-beam tomographies (CBCT) and the use of 3D digital planning software, the best moment of treatment to place dental implants, and the integration of orthodontics in implantology. Results Most participants did not request CBCT (90.8%) or 3D digital planning software images (92.3%…

030213 general clinical medicineCross-sectional studymedicine.medical_treatmentSpecialtyMEDLINEOrtodònciaDentistryOrthodonticsJaw edentulous partiallySurveysEnquestesOsseointegration03 medical and health sciences0302 clinical medicineMultidisciplinary approachimplantologymedicineOral rehabilitationMaloclusióDental implantGeneral DentistryCross-sectional studyOral Medicine and PathologyRehabilitationbusiness.industryResearchDental implants030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseUNESCO::CIENCIAS MÉDICASCross-sectional studiesMalocclusionbusinessPartially edentulousMalocclusion
researchProduct

Mineral profiles of legumes and fruits through partial least squares energy dispersive X-ray fluorescence

2019

Abstarct Energy dispersive X-ray fluorescence (ED-XRF) has been employed for the determination of mineral elements in 15 varieties of legumes and 14 cherry samples. ED-XRF signals directly obtained from pulverized samples were modelized by partial least squares (PLS) using Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) of a selected number of samples, after microwave assisted acid digestion, as reference data. Models were built to predict the concentration of Al, Ca, Cu, Fe, K, Mg, P, Sr and Zn. Average concentrations predicted were 6, 930, 7, 40, 6400, 990, 2100, 4 and 15 μg g−1 for Al, Ca, Cu, Fe, K, Mg, P, Sr and Zn, respectively with relative errors from 7 till 26%. …

0303 health sciencesMaterials scienceMineral030309 nutrition & dietetics010401 analytical chemistryReference data (financial markets)Analytical chemistryX-ray fluorescence01 natural sciencesFluorescence0104 chemical sciences03 medical and health sciencesPartial least squares regressionInductively coupled plasmaOptical emission spectrometryEnergy (signal processing)Food ScienceJournal of Food Composition and Analysis
researchProduct

A continuous time tug-of-war game for parabolic $p(x,t)$-Laplace type equations

2019

We formulate a stochastic differential game in continuous time that represents the unique viscosity solution to a terminal value problem for a parabolic partial differential equation involving the normalized $p(x,t)$-Laplace operator. Our game is formulated in a way that covers the full range $1<p(x,t)<\infty$. Furthermore, we prove the uniqueness of viscosity solutions to our equation in the whole space under suitable assumptions.

050208 financeLaplace transformApplied MathematicsGeneral MathematicsTug of warProbability (math.PR)010102 general mathematics05 social sciencesMathematical analysisType (model theory)01 natural sciencesParabolic partial differential equationTerminal valueMathematics - Analysis of PDEs0502 economics and businessDifferential gameFOS: Mathematics91A15 49L25 35K650101 mathematicsViscosity solutionMathematics - ProbabilityAnalysis of PDEs (math.AP)Mathematics
researchProduct